PLURI INC (PLUR) Stock Price, Forecast & Analysis

NASDAQ:PLUR • US72942G2030

3.66 USD
-0.02 (-0.54%)
Last: Feb 20, 2026, 08:00 PM

PLUR Key Statistics, Chart & Performance

Key Statistics
Market Cap33.85M
Revenue(TTM)234.00K
Net Income(TTM)-22.55M
Shares9.25M
Float4.92M
52 Week High7.13
52 Week Low2.82
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-10.32
PEN/A
Fwd PEN/A
Earnings (Next)05-11
IPO2007-12-10
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
PLUR short term performance overview.The bars show the price performance of PLUR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

PLUR long term performance overview.The bars show the price performance of PLUR in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of PLUR is 3.66 USD. In the past month the price increased by 11.25%. In the past year, price decreased by -15.47%.

PLURI INC / PLUR Daily stock chart

PLUR Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to PLUR. When comparing the yearly performance of all stocks, PLUR is a bad performer in the overall market: 78.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
PLUR Full Technical Analysis Report

PLUR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PLUR. Both the profitability and financial health of PLUR have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PLUR Full Fundamental Analysis Report

PLUR Financial Highlights

Over the last trailing twelve months PLUR reported a non-GAAP Earnings per Share(EPS) of -10.32. The EPS increased by 26.7% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -66.97%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%7.03%
EPS 1Y (TTM)26.7%
Revenue 1Y (TTM)N/A
PLUR financials

PLUR Forecast & Estimates

7 analysts have analysed PLUR and the average price target is 12.24 USD. This implies a price increase of 234.43% is expected in the next year compared to the current price of 3.66.


Analysts
Analysts82.86
Price Target12.24 (234.43%)
EPS Next Y87.65%
Revenue Next YearN/A
PLUR Analyst EstimatesPLUR Analyst Ratings

PLUR Ownership

Ownership
Inst Owners14.91%
Ins Owners9.86%
Short Float %0.45%
Short Ratio0.82
PLUR Ownership

PLUR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.48396.512B
AMGN AMGEN INC16.63202.199B
GILD GILEAD SCIENCES INC16.97187.492B
VRTX VERTEX PHARMACEUTICALS INC23.39119.063B
REGN REGENERON PHARMACEUTICALS16.7882.713B
ALNY ALNYLAM PHARMACEUTICALS INC50.1944.834B
INSM INSMED INC N/A34.336B
NTRA NATERA INC N/A30.104B
BIIB BIOGEN INC12.6228.19B
UTHR UNITED THERAPEUTICS CORP16.0620.691B

About PLUR

Company Profile

PLUR logo image Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.

Company Info

PLURI INC

Matam Advanced Technology Park, Building No. 5

Haifa IL

Employees: 106

PLUR Company Website

PLUR Investor Relations

Phone: 972747107171

PLURI INC / PLUR FAQ

What does PLURI INC do?

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.


Can you provide the latest stock price for PLURI INC?

The current stock price of PLUR is 3.66 USD. The price decreased by -0.54% in the last trading session.


Does PLUR stock pay dividends?

PLUR does not pay a dividend.


What is the ChartMill rating of PLURI INC stock?

PLUR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is PLURI INC (PLUR) stock traded?

PLUR stock is listed on the Nasdaq exchange.


What sector and industry does PLURI INC belong to?

PLURI INC (PLUR) operates in the Health Care sector and the Biotechnology industry.


Can you provide the number of employees for PLURI INC?

PLURI INC (PLUR) currently has 106 employees.